Wounds : a compendium of clinical research and practice · 2025
Pyoderma gangrenosum secondary to chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mager Layna, McFeeters Jacob, Plaza Jose A, Dulmage Brittany, Kaffenberger Benjamin H
Аннотация
BACKGROUND: Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis characterized by rapidly progressive ulcers. PG manifests clinically as painful ulcers with undetermined violaceous borders. A case of diffuse large B-cell lymphoma with cutaneous involvement treated with chimeric antigen receptor T-cell (CAR T-cell) therapy with subsequent development of PG is presented.
CASE REPORT: Based on her clinical presentation, the patient was started on a prednisone taper with wound vacuum. Complete granulation and 90% reepithelialization were noted at 3-month follow-up. The wound was fully resolved within 4 months, without subsequent reactions.
CONCLUSION: The relationship between CAR T-cell therapy and PG remains unknown. In this case, excellent response was achieved using standard treatment for PG wounds, which included prednisone taper and appropriate wound care. The discovery of novel cutaneous manifestations resulting from immunotherapy treatment remains essential for targeted therapy and further management of post-radiation site reactions. More research is needed to determine the significance of CAR T-cell therapy on post-treatment reactions, including PG.
CASE REPORT: Based on her clinical presentation, the patient was started on a prednisone taper with wound vacuum. Complete granulation and 90% reepithelialization were noted at 3-month follow-up. The wound was fully resolved within 4 months, without subsequent reactions.
CONCLUSION: The relationship between CAR T-cell therapy and PG remains unknown. In this case, excellent response was achieved using standard treatment for PG wounds, which included prednisone taper and appropriate wound care. The discovery of novel cutaneous manifestations resulting from immunotherapy treatment remains essential for targeted therapy and further management of post-radiation site reactions. More research is needed to determine the significance of CAR T-cell therapy on post-treatment reactions, including PG.